Early-onset postpartum depression has been shown to have a unique neurobiological basis compared to major depressive disorder, implying a need for targeted treatments such as the recent Food and Drug Administration (FDA)-approved brexanolone. In this case report, a woman with a past medical history of major depressive disorder was diagnosed with postpartum depression due to worsening mood with suicidal and homicidal ideations. She was treated with vilazodone and aripiprazole with good effect after consideration of her past medication trials. Her regimen is unique in clinical practice and not reported in current literature for the treatment of postpartum depression. It may represent a safe and effective medication choice, especially in the context of current first-line treatments that have a high treatment failure rate. More research is needed to find treatments that address the unique challenges of postpartum women.
Published In/Presented At
Yoon J, Gu J, Martin KB. A Novel Treatment of Postpartum Depression and Review of Literature. Cureus. 2022;14(2):e22373. Published 2022 Feb 18. doi:10.7759/cureus.22373
Medicine and Health Sciences | Psychiatry
Department of Psychiatry